Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Chien

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignanciesAmy J Chien, Julie A Illi, Andrew H Ko, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
Creation of de novo cryptic splicing for ALS/FTD precision medicineOscar G Wilkins, Max Z Y J Chien, Josette J Wlaschin, et al.
Scientific Reports|February 8, 2014
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C statusJ M Cunningham, M S Cicek, N B Larson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trialC H Barcenas, S A Hurvitz, J A Di Palma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2020
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survivalM J M Magbanua, L B Swigart, H-T Wu, et al.
Science (New York, N.Y.)|October 3, 2024
Creation of de novo cryptic splicing for ALS and FTD precision medicineOscar G Wilkins, Max Z Y J Chien, Josette J Wlaschin, et al.
Nature Neuroscience|October 21, 2025
TDP-43 loss induces cryptic polyadenylation in ALS/FTDSam Bryce-Smith, Anna-Leigh Brown, Max Z Y J Chien, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignanciesAmy J Chien, Julie A Illi, Andrew H Ko, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
Creation of de novo cryptic splicing for ALS/FTD precision medicineOscar G Wilkins, Max Z Y J Chien, Josette J Wlaschin, et al.
Scientific Reports|February 8, 2014
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C statusJ M Cunningham, M S Cicek, N B Larson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trialC H Barcenas, S A Hurvitz, J A Di Palma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2020
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survivalM J M Magbanua, L B Swigart, H-T Wu, et al.
Science (New York, N.Y.)|October 3, 2024
Creation of de novo cryptic splicing for ALS and FTD precision medicineOscar G Wilkins, Max Z Y J Chien, Josette J Wlaschin, et al.
Nature Neuroscience|October 21, 2025
TDP-43 loss induces cryptic polyadenylation in ALS/FTDSam Bryce-Smith, Anna-Leigh Brown, Max Z Y J Chien, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
Pageof 15